Mefoglip DS Tablet
Glipizide + Metformin Hydrochloride
5 mg+500 mg
Incepta Pharmaceuticals Ltd.
| Pack size | 30's Pack |
|---|---|
| Unite Price | 3.70 BDT |
Indications
Mefoglip DS Tablet is used for:
Type 2 DM
Adult Dose
Type 2 Diabetes Mellitus
Initial treatment: start at 2.5 mg/250 mg (glipizide/metformin) PO qDay with food
If fasting plasma glucose = 280-320 mg/dL: 2.5/500 mg PO q12hr
May adjust daily dose in increments of 1 tab every 2 wk.
Max: Glipizide 10 mg and metformin 2,000 mg daily.
Type 2 DM Inadequately Controlled on Sulfonylurea &/or Metformin
2nd-line treatment: Start at 2.5/500 mg or 5/500 mg PO q12hr with food
May adjust daily dose in increments of not more than 5 mg/500 mg.
Max: Glipizide 20 mg and metformin 2,000 mg daily.
Hepatic impairment: Contraindicated.
Child Dose
Renal Dose
Renal impairment: Serum creatinine (SCr) >1.5 mg/dL (males) or >1.4 mg/dL (females)
Obtain eGFR before starting metformin
eGFR <30 mL/min/1.73 m²: Contraindicated
eGFR 30-45 mL/min/1.73 m²: Not recommended to initiate treatment
Monitor eGFR at least annually or more often for those at risk for renal impairment (eg, elderly)
If eGFR falls below 45mL/min/1.73 m² while taking metformin, risks and benefits of continuing therapy should be evaluated
If eGFR falls below 30 mL/min/1.73 m²: while taking metformin, discontinue the drug
Administration
Should be taken with food.
Contra Indications
Hypersensitivity. Type 2 diabetes mellitus; ketoacidosis; severe renal or hepatic insufficiency, diabetic coma, cardiac failure, recent MI, CHF. IDDM; severe infection; acute or chronic metabolic acidosis with or without coma; stress, trauma; severe impairment of thyroid function; dehydration, acute or chronic alcoholism. Pregnancy, lactation.
Precautions
Hypoglycaemia, stress, elderly. Thyroid impairment, monitor blood-glucose conc and renal function regularly.
Lactation: enters breast milk; not recommended
Pregnancy-Lactation
Pregnancy Category: C
Lactation: enters breast milk; not recommended
Interactions
Glipizide: Decreased effect with beta-blockers, cholestyramine, hydantoins, thiazide diuretics and urinary alkalinizers.
Metformin: Additive effect with sulphonylureas. Antagonistic effects with diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers and isoniazid.
Potentially Fatal: Glipizide: Increased glipizide levels and effects with fluconazole, gemfibrozil, ketoconazole, NSAIDs, pioglitazone and sulfonamides. Increased hypoglycaemic effects with H2 antagonists, anticoagulants, androgens, cimetidine, salicylates, tricyclic antidepressants, probenecid, MAOIs, methyldopa, digitalis glycosides and urinary acidifiers.
Metformin: Lactic acidosis with alcohol and potentiation of hypoglycaemic effect. Cimetidine and furosemide may increase plasma-metformin levels. Drugs eliminated via renal tubular secretion may increase metformin levels.
Side Effects
Side effects of Glipizide + Metformin Hydrochloride :
Glipizide: GI upsets, diarrhoea, nausea; allergic skin reactions, leucopaenia, thrombocytopaenia, agranulocytosis, hyponatraemia; jaundice; haemolytic anaemia, pancytopaenia.
Metformin: Anorexia, nausea, vomiting, diarrhoea, wt loss, flatulence, occasional metallic taste; weakness; hypoglycaemia; rash, malabsorption of Vitamin
Potentially Fatal: Glipizide: Hypoglycaemia in presence of renal or hepatic damage and alcohol. Metformin: Lactic acidosis in presence of renal failure and alcoholism.
Mode of Action
Glipizide stimulates insulin release from pancreatic beta-cells and reduces gluconeogenesis in liver cells. It also increases insulin sensitivity at target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
Note
Mefoglip DS 5 mg+500 mg Tablet generic name is Glipizide + Metformin Hydrochloride. Mefoglip DS 5 mg+500 mg Tablet is manufactured by Incepta Pharmaceuticals Ltd.Mefoglip DS is availble in all over Bangladesh.
Mes BD drug index information on Mefoglip DS Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.